Coronavirus Clinical Trial
— Cov-CONTACTOfficial title:
Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection
Verified date | July 2021 |
Source | Institut National de la Santé Et de la Recherche Médicale, France |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In December 2019, a pneumonia due to a novel coronavirus (SARS-CoV-2) emerged in the city of Wuhan, in China. In a few weeks, the number of confirmed cases of SARS-CoV-2 infection has dramatically increased, with almost 150'000 cases and more than 6'000 reported deaths on March, 16th 2020. Little is known on the rate of human-to-human transmission of this new coronavirus SARS-CoV-2 in the community and within the hospital. Depending on the country, contact subjects considered to be at high or moderate risk of SARS-CoV-2 are, either isolated at home for a period of time defined by the health authorities or, on the contrary, continue their professional activity on the condition that they adopt measures to prevent transmission to those around them. In most European countries, healthcare workers adopt this second option. In all cases, it is most often recommended that contact persons monitor their state of health and communicate it to the persons dedicated to this action. Whether such subjects become spreaders of the virus is not known, nor is the proportion of viral spreader who will develop a symptomatic infection.
Status | Suspended |
Enrollment | 345 |
Est. completion date | December 4, 2022 |
Est. primary completion date | December 4, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: 1. High/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case; 2. Within the 14 days following the last contact with a laboratory-confirmed SARS-CoV-2 case; 3. Obtaining informed consent. Exclusion Criteria: - Subject deprived of freedom - Subject under a legal protective measure |
Country | Name | City | State |
---|---|---|---|
France | Service de maladies infectieuses et tropicales Hôpital Jean Minjoz CHRU Besançon | Besançon | |
France | Service des Maladies infectieuses et tropicales, Pôle Spécialités médicales, CHU Pellegrin | Bordeaux | |
France | Service des maladies infectieuses Hôpital Gabriel Montpied CHU de Clermont Ferrand | Clermont-Ferrand | |
France | Centre d'investigation clinique 1432 Hôpital François Mitterrand CHU Bourgogne | Dijon | |
France | Centre d'investigation clinique 1406 CHU Grenoble | Grenoble | |
France | Centre d'Investigation Clinique 1403 -CHU Lille | Lille | |
France | Centre Investigation Clinique 1433 CHRU de NANCY | Nancy | |
France | Centre d'investigation Clinique 1425, Hôpital Bichat Claude Bernard | Paris | |
France | Centre d'Investigation Clinique Hôpital Saint Louis | Paris | |
France | Centre Investigation Clinique 1417 Hôpital Cochin Bâtiment Lavoisier | Paris | |
France | Centre d'investigation clinique 1414 Service de Pharmacologie clinique CHU Rennes Hôpital Pontchaillou | Rennes | |
France | Centre Hospitalier Félix Guyon Ile de la Réunion CHU nord | Saint Denis | |
France | Département maladie infectieux CHU Saint Etienne | Saint-Étienne | |
France | Centre d'Investigation Clinique Ile de la Réunion CHU sud | Saint-Pierre | |
France | Centre Investigation Clinique 1415 CHRU Tours - Hôpital Bretonneau | Tours | |
French Guiana | Service de Maladies infectieuses et tropicales Centre hospitalier | Cayenne |
Lead Sponsor | Collaborator |
---|---|
Institut National de la Santé Et de la Recherche Médicale, France |
France, French Guiana,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to SARS-CoV-2 nasopharyngeal excretion, from the day of the first high/moderate risk contact to 12 days after the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case. | PCR at day 0, day 3, day 5, day 7 and day 12 following the last high/moderate risk contact | 12 days (+/-2) | |
Secondary | Time to apparition of any symptom suggestive of SARS-CoV-2 from the day of the first high/moderate risk contact to 12 days after the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case. | Patient Reported Outcome assessed daily (fever > 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhea, abdominal pain, ...) | 12 days (+/-2) | |
Secondary | Factors associated with the time to SARS-CoV-2 nasopharyngeal excretion | nasopharyngeal excretion assessed by PCR at day 0, day 3, day 5, day 7 and day 12 following the last high/moderate risk contact | 12 days (+/-2) | |
Secondary | Factors associated with the time to apparition of any symptom suggestive of SARS-CoV-2 infection | Patient Reported Outcome assessed daily (fever > 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhea, abdominal pain, ...) | 12 days (+/-2) | |
Secondary | Proportion of contact subjects with apparition of any symptom suggestive of SARS-CoV-2 infection | Patient Reported Outcome assessed daily (fever > 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhea, abdominal pain, ...) | 12 days (+/-2) | |
Secondary | Proportion of contact subjects with positive serology defined as the presence of SARS-CoV-2 IgM or IgG at day 30 (+/-7) following last contact | ELISA, microneutralisation essay | 30 days (+/-7) | |
Secondary | Host genetic variants | Whole exome sequencing | 1 day | |
Secondary | The time (days) between the first positive SARS-CoV-2 serology and the first negative SARS-CoV-2 serology. | ELISA, microneutralisation essay | 365 days (+/-30) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05065827 -
Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
|
||
Recruiting |
NCT05359770 -
Association of Inspiratory Muscle Training With HD-tDCS for Assistance to Patients With Long Covid-19
|
N/A | |
Completed |
NCT04515147 -
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
|
Phase 2 | |
Not yet recruiting |
NCT06025812 -
Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)
|
N/A | |
Recruiting |
NCT05289115 -
Protocol for Assistance to Patients With Long Covid-19 Undergoing Treatment With HD-tDCS
|
N/A | |
Completed |
NCT04953078 -
A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19
|
Phase 1 | |
Completed |
NCT04779138 -
Increasing Vaccine Uptake in Underresourced Public Housing Areas
|
N/A | |
Not yet recruiting |
NCT05868239 -
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
|
N/A | |
Completed |
NCT04690413 -
NOWDx Test for the Detection of Antibodies to COVID-19
|
N/A | |
Completed |
NCT04818164 -
Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome
|
||
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Completed |
NCT04572399 -
UVA Light Device to Treat COVID-19
|
N/A | |
Recruiting |
NCT04610567 -
Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04772170 -
Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
|
||
Recruiting |
NCT04581954 -
Inflammatory Signal Inhibitors for COVID-19 (MATIS)
|
Phase 1/Phase 2 | |
Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
Enrolling by invitation |
NCT04484025 -
SPI-1005 Treatment in Moderate COVID-19 Patients
|
Phase 2 | |
Completed |
NCT05572840 -
Wear Your Mask, Wash Your Hands, Don't Get COVID-19
|
N/A | |
Withdrawn |
NCT04838847 -
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
|
Phase 3 | |
Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 |